Cancer Monitoring

Sensitive ctDNA and urine-based tests for minimal residual disease (MRD) detection, treatment response monitoring, and non-invasive bladder cancer surveillance.

Cxbladder® Monitor is a urine genomic test designed for patients with non-muscle invasive bladder cancer (NMIBC) who require surveillance monitoring for recurrence. It offers a non-invasive alternative that can reduce the burden of repeated cystoscopy. In suitable patients with sustained negative results, Monitor can replace cystoscopy in the long term following shared decision-making between clinician and patient.

Non-invasive urine genomic test for NMIBC recurrence surveillance. Reduces cystoscopy burden.

Cxbladder® Monitor | Bladder Cancer Surveillance Test | Codex Genetics

Non-invasive urine test for recurrent NMIBC surveillance. Can alternate with or replace cystoscopy in suitable patients, reducing invasive monitoring burden.

Cxbladder® Monitor

Guardant Reveal™ is a blood-based ctDNA test used after curative-intent treatment to assess minimal residual disease (MRD) and monitor for molecular recurrence over time. It combines epigenomic (methylation) and genomic signal detection to improve sensitivity without requiring tumor tissue for assay design.

For appropriate patients, results can support post-treatment risk stratification, adjuvant therapy discussions, and longitudinal surveillance planning. Clinical interpretation should always be integrated with stage, pathology, imaging, and multidisciplinary clinical judgment.

Guardant Reveal is a tissue-free blood test for ctDNA MRD assessment and longitudinal recurrence monitoring, with strong colorectal cancer evidence support.

Guardant Reveal™ | Blood-Based ctDNA MRD & Recurrence Monitoring

Tissue-free ctDNA MRD and recurrence monitoring test using methylation and genomic signals from a simple blood draw.

Guardant Reveal™

癌症监测

利用高灵敏度液态活检技术，监测术后微小残留病灶及癌症复发。

Cxbladder® Monitor 是一项尿液基因检测，适用于需监测复发的非肌层浸润性膀胱癌（NMIBC）患者。该检测提供非侵入性替代方案，可减少重复膀胱镜检查造成的负担。对于持续阴性且条件合适的患者，在医患共享决策下，长期可考虑以该检测替代膀胱镜。

用于 NMIBC 复发监测的非侵入性尿液基因检测，协助降低膀胱镜随访负担。

Cxbladder® Monitor｜膀胱癌随访监测检测｜Codex Genetics

用于 NMIBC 复发监测的非侵入性尿液检测。对合适患者可与膀胱镜交替，或在特定条件下替代膀胱镜以降低监测负担。

Guardant Reveal™ 是一项血液型 ctDNA 检测，可在根治性治疗后用于评估微小残留疾病（MRD）并进行长期分子复发监测。该检测结合表观基因组（甲基化）与基因组信号，以提升灵敏度，且无需肿瘤组织即可执行。

检测结果可支持术后风险分层、辅助治疗讨论与随访规划。最终判读仍需结合分期、病理、影像与多学科临床评估。

Guardant Reveal 为无需组织的血液 ctDNA 检测，用于 MRD 评估与长期复发监测，在结直肠癌具较完整证据支持。

Guardant Reveal™｜血液 ctDNA MRD 与复发监测

以血液样本进行的无需组织 ctDNA MRD 与复发监测检测，结合甲基化与基因组信号。

癌症監測

利用高靈敏度液態活檢技術，監測術後微小殘留病灶及癌症復發。

Cxbladder® Monitor 是一項尿液基因檢測，適用於需監測復發的非肌層浸潤性膀胱癌（NMIBC）患者。此檢測提供非侵入性替代方案，可減少重複膀胱鏡檢查造成的負擔。對於持續陰性且條件合適的患者，在醫病共享決策下，長期可考慮以本檢測取代膀胱鏡。

用於 NMIBC 復發監測的非侵入性尿液基因檢測，協助降低膀胱鏡追蹤負擔。

Cxbladder® Monitor｜膀胱癌追蹤監測檢測｜Codex Genetics

用於 NMIBC 復發監測的非侵入性尿液檢測。對合適患者可與膀胱鏡交替，或在特定條件下取代膀胱鏡以降低監測負擔。

Guardant Reveal™ 是一項血液型 ctDNA 檢測，可在治療後用於評估微小殘留疾病（MRD）並進行長期分子復發監測。此檢測結合表觀基因體（甲基化）與基因體訊號，以提升靈敏度，且無需腫瘤組織即可執行。

檢測結果可支援術後風險分層、輔助治療討論與追蹤規劃。最終判讀仍需結合分期、病理、影像與多專科臨床評估。

Guardant Reveal 為無需組織的血液 ctDNA 檢測，用於 MRD 評估與長期復發監測，於結直腸癌具較完整證據支持。

Guardant Reveal™｜血液 ctDNA MRD 與復發監測

以血液樣本進行的無需組織 ctDNA MRD 與復發監測檢測，結合甲基化與基因體訊號。

Cancer Monitoring

Available Tests

Cxbladder® Monitor

Guardant Reveal™

Quick Links

Resources

Newsletter